Endothelin and Atrial Natriuretic Peptide in Non-Insulin-Dependent Diabetic Versus Nondiabetic Patients on Chronic Hemodialysis

References

• Held P J, Port F K, Gaylin D S, et al. United states renal data system 1993 annual data report. Am J Kidney Dis 1993; 22(suppl 2)1–118
   Google Scholar
• Raine A EG, Margreiter R, Brunner F P, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7(suppl 2)7–35
   PubMed Web of Science ®Google Scholar
• Lerman A, Edwards B S, Hallett J W, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997–1001
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Benigni A. Endothelins in the control of cardiovascular and renal function. Lancet 1993; 342: 589–593
   PubMed Web of Science ®Google Scholar
• Takahashi K, Ghatei M A, Lam H C, et al. Elevated plasma endothelin in patients with diahetes mellitus. Diabetologia 1990; 33: 306–310
   PubMed Web of Science ®Google Scholar
• Collier A, Leach J P, McLellan A, et al. Plasma endothelinlike immunoreactivity levels in IDDM patients with microalbuminuria. Diabetes Care 1992; 15: 1038–1040
   PubMed Web of Science ®Google Scholar
• Kawamura M, Ohgawara H, Naruse M, et al. Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care 1992; 15: 1306–1397
   Google Scholar
• Nord E P. Renal actions of endothelin. Kidney Int 1993; 44: 451–463
   PubMed Web of Science ®Google Scholar
• Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44: 440–444
   PubMed Web of Science ®Google Scholar
• Fukada Y, Hirata Y, Yoahima H, et al. Endothelin is a polent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes. Biochem Biophys Res Commun 1988; 155: 167–172
   Google Scholar
• Ortola F V, Ballermann B J, Anderson S, et al. Elevated plasma atrial natriuretic peptide levels in diabetic rats: potential inediator of hyperfiltration. J Clin Invest 1987; 80: 670–674
   PubMed Web of Science ®Google Scholar
• Perico N, Benigni A, Gabanelli M, et al. Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes 1992; 41: 537–538
   Google Scholar
• Lieberman J S, Parra L, Newton L, et al. Atrial natriuretic peptide and response to changing plasma volume in diabetic nephropathy. Diabetes 1991; 40: 893–901
   Google Scholar
• Sawicki P T, Heinemann L, Rave K, et al. Atrial natriuretic factor in Various stages of diabetic nephropathy. J Diabetic Complic 1988; 4: 207–209
   Google Scholar
• Shinoda T, Ishihara M, Kurimoto F, et al. Elevated plasma atrial natriuretic peptide level in the early phase of microalbuminuria in patients with non-insulin-dependent diabetes mellitus. Clin Nephrol 1990; 34: 202–207
   Google Scholar
• Dussaule J C, Grimaldi A, Czekalski S, et al. Atrial natriuretic peptide in diabetic patients with microangiopathy. Horm Metab Res 1988; 20: 592–594
   Google Scholar
• Rahman N, Kim G, Mathews C, et al. Atrial natriuretic peptide increases creatinine clearance and reduces need for dialysis in patients with established acute renal failure. J Am Soc Nephrol 1993; 5: 323, abstr
   Google Scholar
• Warrens A N, Cassidy M JD, Takahashi K, et al. Endothelin in renal failure. Nephrol Dial Transplant 1990; 5: 418–422
   PubMed Web of Science ®Google Scholar
• Deray G, Carayon A, Maistre G, et al. Endothelin in chronic renal failure. Nephrol Dial Transplant 1992; 7: 300–305
   PubMed Web of Science ®Google Scholar
• Mallamaci F, Parlongo S, Zoccali C. Infiuence of cardiovascular damage and residual renal function on plasma endothelin in chronic renal failure. Nephron 1903; 63: 291–295
   Google Scholar
• Saxenhofer H, Gnädinger M, Weidmann P, et al. Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure. Kidney Int 1987; 32: 554–561
   PubMedGoogle Scholar
• Deray G, Maistre G, Basset J Y, et al. Plasma levels of atrial natriuretic peptide in chronically dialyzed patients. Kidney Int 1988; 34(suppl 25)S86–S88
   Google Scholar
• Artner-Dworzak E, Lindner H, Puschendorf B. In vitro stability of human atrial natriuretic peptide. Clin Chim Acta 1991; 203: 235–242
   Google Scholar
• Schleicher E D, Vogt B W. Srandardization of serum fructosamine assay. Clin Chem 1990; 36: 136–139
   Google Scholar
• Ohta K, Hirata Y, Shichiri M, et al. Urinary excretion of endothelin-l in normal subjects and patients with renal disease. Kidney Int 1991; 39: 307–311
   PubMed Web of Science ®Google Scholar
• Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993; 43: 354–358
   PubMed Web of Science ®Google Scholar
• Koyama H, Nishzawa Y, Morii H, et al. Plasma endothelin levels in patients with uremia. Lancet 1989; 1: 991–992
   PubMed Web of Science ®Google Scholar
• Toshimitsu N, Toshitaka F, Kanji U, et al. Effect of hernodialysis on plasma levels of vasoactive peptides: endothelin, calcitonin gene-related peptide and human atrial natriuretic peptide. Nephron 1993; 64: 552–559
   Google Scholar
• Kohno M, Yasunari K, Murakawa K, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88: 614–618
   PubMed Web of Science ®Google Scholar
• Lerman A, Hildebrand F L, Aarhus L L, et al. Endothelin has biological actions at pathophysiological concentrations. Circulation 1991; 83: 1808–1814
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Ohnaka T, Takayanagi R, et al. Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990; 267: 16–18
   PubMed Web of Science ®Google Scholar
• Haak T, Jungmann E, Felber A, et al. Increased plasma levels of endothelin in diabetic patients with hypertension. Am J Hypertens 1992; 5: 161–166
   PubMed Web of Science ®Google Scholar
• Heintz B, Königs F, Dakshinamurty K V, et al. Response of vasoactive substances to intermittent ultrafiltration in normotensive hemodialysis patients. Nephron 1993; 65: 266–272
   PubMed Web of Science ®Google Scholar
• Kohse K P, Feifel K, Mayer-Wehrstein R. Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients. Clin Nephrol 1993; 40: 83–90
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Ciccarelli M, et al. The influence of autonomic failure on plasma ANF concentration in uremic patients on chronic hemodialysis. Clin Nephrol 1992; 37: 198–203
   Google Scholar
• Awazu M, Ichikawa I. Biological significance of atrial natriuretic peptide in the kidney. Nephron 1993; 63: 1–14
   PubMedGoogle Scholar
• Zuber M, Kiowski W, Huser B, et al. Atrial natriuretic peptide release and volume regulation following kidney transplantation. Clin Nephrol 1993; 40: 91–95
   Google Scholar
• Hornberger J C, Petersen J. Atrial natriuretic peptide, renal failure, and dialysis. Sem Dial 1990; 3: 178–181
   Google Scholar
• Tan A CITL, Rosmalen F MA, Theelen B GA, et al. Atrial natriuretic peptide—the influence of various physiological and sampling conditions. Ann Clin Biochem 1987; 24: 500–507
   Google Scholar
• Goto K, Kasuya Y, Matsuki N, et al. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc Natl Acad Sci USA 1989; 86: 3915–3918
   PubMed Web of Science ®Google Scholar
• Liu J J, Casley D, Wojta J, et al. Reduction of endothelin levels by the dihydropyridine calcium antagonist nisoldipine and a “natural factor” in cultured human endothelial cells. J Hypertens 1993; 11: 977–982
   Google Scholar
• Sunman W, Martin G, Hair W M, et al. Effect of calcium antagonists on endothelin-induced contraction of imlated human resistance arteries: differences related to site of origin. J Hum Hypertens 1993; 7: 189–191
   Google Scholar
• Erbas B, Ozdernir O, Pasaoglu I, et al. Short- and long-term effects of felodipine on circulating endothelin and atrial natriuretic peptide levels in essential hypertension. Nephron 1993; 63: 363–364
   Google Scholar
• Mohaupt M, Backer A, Meyer-Lehnert H, et al. Increased plasma endothelin reflects renal impairment in arterial hypertension: effects of calcium channel blockade. Nieren- Hochdruckkr 1991; 20: 430, abstr
   Google Scholar
• Zachariah P K, Burnett J C, Ritter S G, et al. Atrial natriuretic peptide in human essential hypertension. Mayo Clin Proc 1987; 62: 782–786
   PubMed Web of Science ®Google Scholar